Madrigal Pharmaceuticals, Inc. (LON:0JXI)
London · Delayed Price · Currency is GBP · Price in USD 301.62
-5.26 (-1.71%)
At close: Aug 1, 2025
Madrigal Pharmaceuticals Company Description
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.
| Country | United States |
| Industry | Pharmaceutical Preparations |
| Employees | 528 |
| CEO | William Sibold |
Contact Details
Address: Four Tower Bridge West Conshohocken, Delaware 19428 United States | |
| Phone | 267 824 2827 |
| Website | madrigalpharma.com |
Stock Details
| Ticker Symbol | 0JXI |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William Sibold | Chief Executive Officer |
| Mardi Dier | Chief Financial Officer |
| Mark Underwood | Chief Operating Officer |
| Tina Ventura | Head of Investor Relations |